BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25583353)

  • 21. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Closing in on human immunodeficiency virus-1.
    Mellors JW
    Nat Med; 1996 Mar; 2(3):274-5. PubMed ID: 8612219
    [No Abstract]   [Full Text] [Related]  

  • 23. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D; Liu MS; Ji B; Hwang KC; Huang Y
    Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Antiviral Activity of Water-Soluble Polycarboxylic Derivatives of [60]Fullerene Loaded with 3,4-Dichlorophenyl Units.
    Voronov II; Martynenko VM; Chernyak AV; Balzarini J; Schols D; Troshin PA
    Chem Biodivers; 2018 Nov; 15(11):e1800293. PubMed ID: 30168652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
    Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
    Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
    Li D; Liu MS; Ji B; Hwang K; Huang Y
    J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
    Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
    J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of New Cationic N,N-Dimethyl[70]fulleropyrrolidinium Iodide Derivatives as Potent HIV-1 Maturation Inhibitors.
    Castro E; Martinez ZS; Seong CS; Cabrera-Espinoza A; Ruiz M; Hernandez Garcia A; Valdez F; Llano M; Echegoyen L
    J Med Chem; 2016 Dec; 59(24):10963-10973. PubMed ID: 28002960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of carbon nanotubes as HIV-1 protease inhibitors: atomistic and coarse-grained simulations.
    Cheng Y; Li D; Ji B; Shi X; Gao H
    J Mol Graph Model; 2010 Sep; 29(2):171-7. PubMed ID: 20580296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.
    Friedman SH; Ganapathi PS; Rubin Y; Kenyon GL
    J Med Chem; 1998 Jun; 41(13):2424-9. PubMed ID: 9632374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.